Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial

Irene Reijers, Elisa A. Rozeman, Alexander M. Menzies, Bart A. Van De Wiel, Hanna Eriksson, Karijn Suijkerbuijk, Astrid Aplonia Maria Van Der Veldt, Ellen Kapiteijn, Geke Hospers, Willem M.C. Klop, Andrew Spillane, Richard A. Scolyer, Inge Marie Svane, Lars Bastholt, Henrik Schmidt, James M.G. Larkin, Alexander Christopher Jonathan Van Akkooi, Georgina V Long, Christian U. Blank

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article numberTPS9605
JournalJournal of Clinical Oncology
Volume37
Issue number15 Suppl.
ISSN0732-183X
DOIs
Publication statusPublished - 2019
EventASCO - Chicago, United States
Duration: 31. May 20194. Jun 2019

Conference

ConferenceASCO
Country/TerritoryUnited States
CityChicago
Period31/05/201904/06/2019

Cite this